Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High dose of dialysis Clear all

Conditions: Renal Insufficiency
Interventions: Tirofiban; Drug
Lead sponsor: Medicure; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Multiple Myeloma, Cancer
Interventions: Isatuximab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 2 more

Conditions: Diffuse Glioma, Malignant Glioma
Interventions: Biospecimen Collection, Computed Tomography, Eflornithine, Magnetic Resonance Imaging, Polyamine Transport Inhibitor AMXT-1501 Dicaprate, Resection, Microdialysis, Placement; Procedure · Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: End Stage Kidney Disease
Interventions: CSL300, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 166
States / cities: Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more

Conditions: Acute Renal Failure
Interventions: Standard dose of dialysis, High dose of dialysis; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Dialysis
Interventions: Algorithm model-based Aranesp doses, Standard of care; Procedure
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Murray, Utah

Conditions: Iron Deficiency, Iron Deficiency Anemia
Interventions: Ferric Citrate, Placebo; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Tempe, Arizona • La Mesa, California • Sacramento, California + 17 more

Conditions: Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions: An FDA approved continuous renal replacement device, Control Group; Device · Other
Lead sponsor: American Burn Association; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 9
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more

Conditions: End Stage Renal Disease
Interventions: Ergocalciferol, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions: FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate); Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Iron Deficiency
Interventions: Iron sucrose; Drug
Lead sponsor: The Guthrie Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: End Stage Renal Disease
Interventions: Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis, High dose, high flux hemodialysis; Device
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 1,846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Rochester, New York

Conditions: End-stage Renal Disease
Interventions: ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Torrance, California

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions: Cinacalcet HCl, Standard of Care; Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more

Conditions: Anemia in Incident Dialysis Patients
Interventions: Roxadustat, Epoetin Alfa; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Chula Vista, California • La Mesa, California • San Diego, California + 25 more

Conditions: End-stage Renal Disease
Interventions: oral fructose and high fat diet; Procedure
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperkalemia
Interventions: LOKELMA 5 GM Powder for Oral Suspension; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more

Conditions: COVID-19
Interventions: PF-07321332 (nirmatrelvir)/ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 52
States / cities: Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more

Conditions: Renal Impairment, Tuberculosis
Interventions: PA-824; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • St Louis, Missouri • Knoxville, Tennessee

Search by objective public record fields.

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

High Dose CVVHDF Compared to Standard Dose CVVHDF

Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

DIVINE: Dialysis Infection and Vitamin D In New England

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

The Safety of a High-Dose, Rapid Infusion of Iron Sucrose

Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

Arterial pH and Total Body Nitrogen Balances in APD

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function